Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006 Jan 20; 24(3):437-43.
-
Adult
-
Aged
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols
-
Chromosomes, Human, Pair 11
-
Chromosomes, Human, Pair 17
-
Clinical Trials, Phase II as Topic
-
Disease Progression
-
Disease-Free Survival
-
Female
-
Gene Deletion
-
Genes, Immunoglobulin Heavy Chain
-
Genetic Predisposition to Disease
-
Humans
-
Immunologic Factors
-
Leukemia, Lymphocytic, Chronic, B-Cell
-
Male
-
Middle Aged
-
Mutation
-
Predictive Value of Tests
-
Prognosis
-
Randomized Controlled Trials as Topic
-
Risk Assessment
-
Risk Factors
-
Rituximab
-
Tumor Suppressor Protein p53
-
Vidarabine